KBIO LABS Inc.

As of March 31, 2026, KBIO LABS Inc. carries a market capitalization of 195.19B, placing it among publicly traded companies globally. Its enterprise value stands at 181.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, KBIO LABS Inc. has 23.10M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1.89, and the price-to-book ratio stands at 3.63.

As of March 31, 2026, KBIO LABS Inc. trades at an EV/EBITDA multiple of 138.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 488.07 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 181.92B versus a market cap of 195.19B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, KBIO LABS Inc. maintains a current ratio of 5.84, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.78, indicating moderate leverage, while an interest coverage ratio of 26.54 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, KBIO LABS Inc. posted a negative return on equity (ROE) of -4.25, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.96, reflecting losses generated across the asset base. The company generates approximately 2.33B in revenue per employee across its workforce of 35.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.05 indicates how many times KBIO LABS Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, KBIO LABS Inc. recorded 162.07M in income tax expense. The company reported a pretax loss of -2.62B and -2.34B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, KBIO LABS Inc.'s stock has declined approximately 45.21% over the past 52 weeks. The 50-day moving average sits at 4,272.60, while the 200-day moving average is 6,074.18.

Over the twelve months ended March 31, 2026, KBIO LABS Inc. generated 82.64B in revenue and converted that into -2.34B in net income, yielding earnings per share of -150.50. EBITDA reached 1.32B, while operating income came in at 386.91M.

As of March 31, 2026, KBIO LABS Inc. holds 64.74B in cash and equivalents against 814.40M in total debt, resulting in a net debt position of -28.09B. Total book value stands at 53.81B, with working capital of 69.01B providing operational flexibility.

KBIO LABS Inc. produced 7.94B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -174.93M in capital expenditures, free cash flow totaled 7.76B - equivalent to 420.10 per share.

Over the twelve months ended March 31, 2026, KBIO LABS Inc. posted a gross margin of 13.95, reflecting its pricing power and cost economics. The operating margin of 0.47 and net profit margin of -2.83 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 4.97, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KBIO LABS Inc. shareholders.

KBIO LABS Inc.'s most recent stock split took place on September 21, 2026 with a 5:1 split ratio.

As of March 31, 2026, KBIO LABS Inc. has an Altman Z-Score of 8.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.